一、审议通过了《关于<2023 年半年度报告及摘要>的议案》 证券代码：300049 证券简称：福瑞股份 公告编号：2023-039 内蒙古福瑞医疗科技股份有限公司 第八届监事会第三次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 2023 年 8 月 18 日，本公司以电子邮件方式，向全体监事发出了《关于召开第八届监 事会第三次会议的通知》及相关议案。根据《公司章程》和《监事会议事规则》的有关 规定，公司监事会于 2023 年 8 月 28 日在公司以通讯方式召开了第八届监事会第三次会 议，本次会议为定期会议，监事会主席王立群女士主持了本次会议，会议应参加表决监 事 5 人，实际参加表决监事 5 人。本次会议的召开符合《公司法》和《公司章程》的规 定。 全体出席会议的监事经过认真审议、表决，形成如下决议： 具体内容详见公司于同日刊登在巨潮资讯网上的《2023 年半年度报告》全文及摘要。 监事会认为：公司《2023 年半年度报告》的编制和审核程序符合法律、行政法规和 中国证监会的规定，报告内容真实、准确、完整地反映了公司的实际情况，不存在任何 虚 ...

证券代码：300049 证券简称：福瑞股份 公告编号：2023-040 内蒙古福瑞医疗科技股份有限公司 关于对外捐赠的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、对外捐赠事项概述 内蒙古福瑞医疗科技股份有限公司（以下简称"公司"）于 2023 年 8 月 28 日召开第八 届董事会第三次会议，审议通过了《关于对外捐赠的议案》，同意公司及子公司以自有 资金向各类慈善公益组织捐赠不超过人民币 1000 万元，款项主要用于肝病相关课题研究、 社区筛查等。为保证合法、高效地完成本次捐赠工作，公司董事会授权管理层在上述额 度范围内负责对外捐赠事项的实施。本次对外捐赠额度经公司董事会审议通过之日起 12 个月内有效。 根据《深圳证券交易所创业板股票上市规则》《公司章程》等有关规定，本次捐赠 事项在董事会决策范围内，无需提交公司股东大会审议。本次对外捐赠事项不构成关联 交易，亦不构成《上市公司重大资产重组管理办法》规定的重大资产重组。 二、捐赠目的和对公司的影响 独立董事认为：本次对外捐赠是公司积极履行社会责任、回馈社会的举措，符合公 司的经营宗旨和价值观的要 ...

证券代码：300049 证券简称：福瑞股份 公告编号：2023-038 内蒙古福瑞医疗科技股份有限公司 第八届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2023 年 8 月 18 日，本公司以电子邮件的方式，向全体董事发出了《关于召开第八届 董事会第三次会议的通知》及相关议案。根据《公司章程》和《董事会议事规则》的有 关规定，公司董事会于 2023 年 8 月 28 日以通讯方式召开了第八届董事会第三次会议， 本次会议为定期会议，董事长王冠一先生主持了本次会议。会议应参加表决董事 7 人， 实际参加表决董事 7 人。公司监事、高级管理人员列席了本次会议。本次会议的召开符 合《公司法》和《公司章程》的规定。 公司独立董事对该事项发表了独立意见，详见公司于同日刊登在巨潮资讯网上的《独 立董事关于相关事项的独立意见》。 表决结果：同意 7 票，反对 0 票，弃权 0 票。 三、审议通过了《关于聘任副总经理的议案》 同意聘任卢奕伟先生为公司副总经理，任期与第八届董事会任期一致。具体内容详 见公司于同日刊登在巨潮资讯网上的《关于聘任副总经 ...

内蒙古福瑞医疗科技股份有限公司 2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表 | | | 占用方与上 | 上市公司核 | 2023 年期初 | 2023 年 1 月 1 日至 6 月 30 日 | 2023 年 1 月 1 | 2023 年 1 月 1 | 2023 年 6 月 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性 | 资金占用方 | 市公司的关 | 算的会计科 | 占用资金余 | 占用累计发生 | 日至 6 月 30 | 日至 6月30日 | 30 日占用 | 占用形成原 | 占用性质 | | 资金占用 | 名称 | | | | | 日占用资金 | 偿还累计发生 | | 因 | | | | | 联关系 | 目 | 额 | 金额（不含利 | | | 资金余额 | | | | | | | | | 息） | 的利息(如有) | 金额 | | | | | 控股股东、 | | | | | | | | | | 非经营性占用 | | 实 际 控 制 | | | | | | | | ...

内蒙古福瑞医疗科技股份有限公司 独立董事的独立意见 内蒙古福瑞医疗科技股份有限公司 独立董事关于相关事项的独立意见 根据中国证监会《上市公司独立董事管理办法》、深圳证券交易所《上市公司自律监 管指引第 2 号——创业板上市公司规范运作》等相关法律法规、规章制度的规定，作为内 蒙古福瑞医疗科技股份有限公司（以下简称"公司"）的独立董事，现对公司第八届董事 会第三次会议审议的相关事项发表如下独立意见： 一、独立董事关于公司 2023 年半年度控股股东及其他关联方资金占用情况的独立意见 经对公司 2023 年半年度控股股东及其他关联方资金占用情况进行认真核查：本报告期 内，公司不存在控股股东及其他关联方占用公司资金的情况，截止 2023 年 6 月 30 日，也 不存在以前年度发生并累计至 2023 年 6 月 30 日的违规关联方占用资金情况。 二、独立董事关于公司 2023 年半年度对外担保情况的独立意见 2、根据公司提供的副总经理的简历及其他有关材料，未发现其有《公司法》《深圳证 券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等规定的不得担任 经对公司 2023 年半年度对外担保情况进行认 ...

证券代码：300049 证券简称：福瑞股份 公告编号：2023-041 内蒙古福瑞医疗科技股份有限公司 关于 2023 年半年度计提、转回资产减值准备的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整、没有虚假 记载、误导性陈述或重大遗漏。 经公司测算，2023 年半年度计提各项资产减值准备共计 1,860,150.81 元，收回或转 回资产减值准备 14,995,879.30 元，其他变动 4,696,367.66 元。具体明细如下： 单位：元 | 类别 | 2022 年 12 月 31 | 本期计提 | 本期减少 | | 其他 | 2023 年 6 月 30 | | --- | --- | --- | --- | --- | --- | --- | | | 日余额 | | 收回或转回 | 核销 | | 日余额 | | 应收账款坏账 准备 | 29,329,540.97 | 1,606,560.96 | 9,375,581.85 | | 4,318,953.09 | 25,879,473.17 | | 其他应收款坏 账准备 | 6,391,079.02 | 253,589.85 | 5,620 ...

Group 1: Company Strategy and Development - The company plans to advance the Furui Health Technology Park project, aiming for completion in two years, integrating product R&D, a leading liver disease data center, and internet healthcare [1] - The company has a high management cost primarily due to high average salaries for overseas employees [1] - The company is focusing on the promotion of FibroScan Go, which is expected to increase revenue despite currently low income contribution [2] Group 2: Product and Market Insights - Theraclion's high-intensity focused ultrasound technology is primarily used for non-invasive treatments in varicose veins, thyroid tumors, and breast fibromas [2] - The global liver disease diagnostics market is projected to reach $29.27 billion by 2028, with FibroScan expected to capture a significant market share [4][6] - The NASH drug market is anticipated to grow rapidly, reaching $10.7 billion by 2025 and $32.2 billion by 2030, with compound annual growth rates of 41.8% and 24.6% respectively [6] Group 3: Financial Performance and Shareholder Information - As of May 31, 2023, the company had 13,249 shareholders [2] - The company's self-owned drug revenue increased by 9.33% year-on-year, with a gross margin increase of 1.60% [5] - The company is currently not planning to acquire the remaining 49% stake in Echosens [5] Group 4: Future Collaborations and Innovations - The company is considering further investments in Theraclion based on its development status [4] - There are no current plans for overseas promotion of the compound turtle shell soft liver tablets due to acceptance issues [3] - The company has no ongoing development of innovative drugs at this time [5]

证券代码：300049 证券简称：福瑞股份 公告编号：2023-031 内蒙古福瑞医疗科技股份有限公司 关于参加内蒙古辖区上市公司 2023 年投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 为进一步加强与投资者的互动交流，内蒙古福瑞医疗科技股份有限公司（以下简称 "公司"）将参加由内蒙古证监局、内蒙古上市公司协会与深圳市全景网络有限公司联合 举办的"2023 年内蒙古辖区上市公司投资者集体接待日活动"，现将相关事项公告如下： 本 次 活 动 将 采 用 网 络 远 程 的 方 式 举 行 ， 投 资 者 可 登 录 " 全 景 路 演 " 网 站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参与本次 互动交流，活动时间为 2023 年 6 月 9 日（周五）15:30-17:00。届时公司高管等人员将 在线就公司 2022 年度业绩、公司治理、发展战略、经营状况等投资者关心的问题，与 投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告。 内蒙古福瑞医疗科技股份有限公司董事 ...

Group 1: Financial Performance - The company received a total of 280 million CNY in special government funding, which was distributed in batches over previous years [1] - In 2022, Echosens achieved a revenue of 86.42 million EUR, representing a growth of 21.75% compared to the previous year [2] - As of May 10, 2023, the number of shareholders reached 13,855 [3] Group 2: Product Development and Market Strategy - The company is focusing on the NASH (Non-Alcoholic Steatohepatitis) field, with ongoing clinical trials for multiple NASH drugs [2] - FibroScan, a key product, had over 90% of its sales revenue generated from overseas markets in 2022 [2] - The company launched FibroScan GO in 2022, targeting primary healthcare institutions with a per-use charging model, which is currently being piloted in the US and France [2] Group 3: Research and Development - The company is actively collaborating with major international pharmaceutical companies to support drug clinical trials and provide comprehensive solutions [2] - The current focus in NASH drug development includes companies like Intercept, Madrigal, Pfizer, and others that have reached clinical endpoints [3] - The company is in the early trial phase for its Cordyceps project and cannot yet provide profit contributions [3]

Financial Performance - The company reported total revenue of 611.18 million, with a net profit of 103.44 million, reflecting a profit margin of approximately 16.9%[11]. - The company reported a total revenue of 2.48619 million yuan for the year, with expenses related to employee stock options included in management and sales expenses[50]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion yuan, representing a year-over-year growth of 20%[63]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 25%[63]. - The company’s operating revenue for 2022 was ¥1,008,765,862.03, representing a 12.27% increase from ¥898,483,228.69 in 2021[198]. - Net profit attributable to shareholders for 2022 was ¥97,871,370.77, a 2.52% increase compared to ¥95,468,878.12 in 2021[198]. - The net profit after deducting non-recurring gains and losses was ¥99,663,477.88, which is an 8.62% increase from ¥91,756,578.58 in the previous year[198]. - The basic earnings per share for 2022 was ¥0.3721, reflecting a 1.22% increase from ¥0.3676 in 2021[198]. - The cash flow from operating activities for 2022 was ¥189,461,778.48, a decrease of 14.87% compared to ¥222,552,216.23 in 2021[198]. - Quarterly operating revenue showed consistent growth, with Q4 2022 reaching ¥289,716,738.22, up from ¥209,134,132.83 in Q1 2022[199]. - The net profit attributable to shareholders in Q4 2022 was ¥37,108,764.11, significantly higher than ¥8,643,617.12 in Q1 2022[199]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 2 yuan per 10 shares, totaling 52.61 million, which aligns with its profit distribution policy[23]. - The company has not made any adjustments to its profit distribution policy during the reporting period, maintaining consistency with its established guidelines[22]. - The company plans to distribute a cash dividend of 2 RMB per 10 shares (including tax) to all shareholders, based on a total of 263,053,100 shares[187]. Corporate Governance and Compliance - The company has not reported any significant financial or non-financial reporting deficiencies during the reporting period[30]. - The company is committed to improving corporate governance and compliance with regulations to enhance its operational effectiveness and transparency[31]. - The company has implemented measures to strengthen internal control and auditing, focusing on monitoring significant financial transactions[52]. - The company has not faced any penalties or violations during the reporting period, indicating a stable operational environment[58]. - The company emphasizes the importance of considering the interests and demands of minority shareholders in decision-making processes[167]. - The company has maintained a stable and healthy development in its operations, driven by diligent and responsible board members[167]. Market Expansion and Product Development - The company aims to expand the clinical application of FibroScan in collaboration with major hospitals, targeting increased usage in primary healthcare institutions and departments beyond liver diseases[2]. - The company is focused on developing FibroScan as a key standard in the global NASH testing field, leveraging partnerships with international pharmaceutical companies[2]. - The company has established a global sales network covering over 100 countries, enhancing its market presence in Asia-Pacific, Europe, and North America[2]. - New product launches are expected to contribute an additional 300 million yuan in revenue over the next year[63]. - The company is investing in new technology development, allocating 100 million yuan for R&D initiatives[63]. - Market expansion plans include entering three new provinces, aiming for a 10% market share in these regions within two years[63]. - The company completed the acquisition of a smaller competitor, which is expected to enhance its market position and add 200 million yuan in annual revenue[63]. - The board has approved a new strategy focusing on digital transformation, with an investment of 50 million yuan planned for the next year[63]. Shareholder Structure and Remuneration - The company reported a total share count of 263,053,100, with 87.70% being unrestricted shares[141]. - The number of restricted shares decreased by 255,000, resulting in a total of 32,353,816 restricted shares, which is 12.30% of the total[141]. - The largest shareholder, Wang Guanyi, holds 22,315,603 restricted shares, which are subject to a 25% annual release[145]. - The company has a diversified shareholder structure with no single entity holding a majority stake[151]. - The total remuneration paid to directors, supervisors, and senior management in 2022 amounted to 6.3751 million yuan[161]. - Wang Guanyi, the chairman, received a pre-tax remuneration of 813,600 yuan[161]. - Lin Xin, the vice chairman and general manager, received a pre-tax remuneration of 1,010,600 yuan[161]. - The company’s board of directors and supervisors' remuneration is determined based on performance, ability, and position level[161]. - The company has implemented a performance evaluation system for senior management to determine their remuneration[161]. Social Responsibility and Environmental Initiatives - The company emphasizes environmental protection and sustainable development, continuously improving production processes and enhancing employee awareness of environmental protection[38]. - The company actively participates in social welfare initiatives, receiving the "2021 Public Welfare Collective Award" and providing 2 million fever-reducing medications to local government and medical units[39]. Financial Stability and Risk Management - The company has maintained a strong balance sheet, with total assets reported at 3 billion yuan and a debt-to-equity ratio of 0.5[63]. - There were no non-operating fund occupations by major shareholders during the reporting period, ensuring financial stability[71]. - The company reported a total investment of 18,780,000 in bank wealth management products, with an outstanding balance of 12,020,000[100]. - The company has no major guarantees during the reporting period[118]. - There were no significant asset or equity acquisitions or sales during the reporting period[95]. - The company maintained a good credit status with no significant debts due[109]. - The company did not experience any major penalties or rectification situations during the reporting period[108]. - The company has not engaged in any high-risk entrusted financial management during the reporting period[119]. - The company has no major contracts or leasing situations during the reporting period[121].